Plasma VAP-1/SSAO activity predicts intracranial hemorrhages and adverse neurological outcome after tissue plasminogen activator treatment in stroke

Stroke

Volumn 41, Issue 7, 2010, Pages 1528-1535

  Hernandez Guillamon, Mar ^a   Garcia Bonilla, Lidia ^a   Solé, Montse ^b   Sosti, Victoria ^a   Parés, Mireia ^a   Campos, Mireia ^a   Ortega Aznar, Arantxa ^c   Domínguez, Carmen ^c   Rubiera, Marta ^a   Ribó, Marc ^a   Quintana, Manolo ^a   Molina, Carlos A ^a   Alvarez Sabín, José ^a   Rosell, Anna ^a   Unzeta, Mercedes ^b   Montaner, Joan ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INSTITUT DE NEUROCIÈNCIES   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

animal model; hemorrhagic transformation; semicarbazide; stroke; thrombolysis; VAP 1 SSAO

Indexed keywords

ALTEPLASE; AMINE OXIDASE (FLAVIN CONTAINING); SEMICARBAZIDE; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR ADHESION PROTEIN 1; AMINE OXIDASE (COPPER CONTAINING); AOC3 PROTEIN, HUMAN; BIOLOGICAL MARKER; CELL ADHESION MOLECULE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN HEMORRHAGE; BRAIN INFARCTION SIZE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RAT; STROKE; ANIMAL; BLOOD; COMPARATIVE STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; MIDDLE AGED; NEUROLOGIC DISEASE; PHYSIOLOGY; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; AMINE OXIDASE (COPPER-CONTAINING); ANIMALS; BIOLOGICAL MARKERS; CELL ADHESION MOLECULES; ENZYME ACTIVATION; FEMALE; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RATS; RATS, SPRAGUE-DAWLEY; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 77954176890     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.584623     Document Type: Article

References (26)

1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333:1581-1587.
2. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D; ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
3. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribó M, Quintana M, Alvarez-Sabín J. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation. 2003;107:598-603.
4. Castellanos M, Leira R, Serena J, Blanco M, Pedraza S, Castillo J, Dávalos A. Plasma cellular-fibronectin concentration predicts hemor-rhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke. 2004;35:1671-1676.
5. Jalkanen S, Salmi M. VAP-1 and CD73, endothelial cell surface enzymes in leukocyte extravasation. Arterioscler Thromb Vasc Biol. 2008;28: 18-26.
6. Koskinen K, Vainio PJ, Smith DJ, Pihlavisto M, Ylä-Herttuala S, Jalkanen S, Salmi M. Granulocyte transmigration through the endotheli-um is regulated by the oxidase activity of vascular adhesion protein-1 (VAP-1). Blood. 2004;103:3388-3395.
7. Boomsma F, van Veldhuisen DJ, de Kam PJ, Man in't Veld AJ, Mosterd A, Lie KI, Schalekamp MA. Plasma semicarbazide-sensitive amine oxidase is elevated in patients with congestive heart failure. Cardiovasc Res. 1997;33:387-391.
8. Boomsma F, van Den Meiracker AH, Winkel S, Aanstoot HJ, Batstra MR, Man in't Veld AJ, Bruining GJ. Circulating semicarbazide-sensitive amine oxidase is raised both in type I (insulin-dependent), in type II (non-insulin-dependent) diabetes mellitus and even in childhood type I diabetes at first clinical diagnosis. Diabetologia. 1999;42:233-237.
9. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE III. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial TOAST Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35-41.
10. Brott TG, Haley EC Jr, Levy DE, Barsan W, Broderick J, Sheppard GL, Spilker J, Kongable GL, Massey S, Reed R, et al. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke. 1992;23:632-640.
11. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Höxter G, Mahagne MH, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017-1025.
12. Lizcano JM, Tipton KF, Unzeta M. Purification and characterization of membrane-bound semicarbazide-sensitive amine oxidase (SSAO) from bovine lung. Biochem J. 1998;331:69-78.
13. Zhang Z, Zhang RL, Jiang Q, Raman SB, Cantwell L, Chopp M. A new rat model of thrombotic focal cerebral ischemia. J Cereb Blood Flow Metab. 1997;17:123-135. (Pubitemid 27085835)
14. Bederson JB, Pitts LH, Germano SM, Nishimura MC, Davis RL, Bart-kowski HM. Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke. 1986;17:1304-1308.
15. Perez-Asensio FJ, Hurtado O, Burguete MC, Moro MA, Salom JB, Lizasoain I, Torregrosa G, Leza JC, Alborch E, Castillo J, Knowles RG, Lorenzo P. Inhibition of iNOS activity by 1400W decreases glutamate release and ameliorates stroke outcome after experimental ischemia. Neu-robiol Dis. 2005;18:375-384.
16. Fowler CJ, Tipton KF. Concentration dependence of the oxidation of tyramine by the two forms of rat liver mitochondrial monoamine oxidase. Biochem Pharmacol. 1981;30:3329-3332.
17. Rosell A, Cuadrado E, Ortega-Aznar A, Hernandez-Guillamon M, Lo EH, Montaner J. MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke. 2008;39:1121-1126.
18. Cuadrado E, Ortega L, Hernández-Guillamon M, Penalba A, Fernández-Cadenas I, Rosell A, Montaner J. Tissue plasminogen activator (t-PA) promotes neutrophil degranulation and MMP-9 release. J Leukoc Biol. 2008;84:207-214.
19. Stolen CM, Marttila-Ichihara F, Koskinen K, Yegutkin GG, Turja R, Bono P, Skurnik M, Hänninen A, Jalkanen S, Salmi M. Absence of the endothelial oxidase AOC3 leads to abnormal leukocyte traffic in vivo. Immunity. 2005;22:105-115.
20. Stolen CM, Yegutkin GG, Kurkijärvi R, Bono P, Alitalo K, Jalkanen S. Origins of serum semicarbazide-sensitive amine oxidase. Circ Res. 2004; 95:50-57.
21. Yu PH, Deng YL. Endogenous formaldehyde as a potential factor of vulnerability of atherosclerosis: involvement of semicarbazide-sensitive amine oxidase-mediated methylamine turnover. Atherosclerosis. 1998; 140:357-363.
22. Garpenstrand H, Ekblom J, von AM, Oreland L, Murray V. Plasma semicarbazide-sensitive amine oxidase in stroke. Eur Neurol. 1999;41: 20-23.
23. Airas L, Lindsberg PJ, Karjalainen-Lindsberg ML, Mononen I, Kotisaari K, Smith DJ, Jalkanen S. Vascular adhesion protein-1 in human ischaemic stroke. Neuropathol Appl Neurobiol. 2008;34:394-402.
24. Kano T, Katayama Y, Tejima E, Lo EH. Hemorrhagic transformation after fibrinolytic therapy with tissue plasminogen activator in a rat throm-boembolic model of stroke. Brain Res. 2000;854:245-248.
25. Xu HL, Salter-Cid L, Linnik MD, Wang EY, Paisansathan C, Pelligrino DA. Vascular adhesion protein-1 plays an important role in postischemic inflammation and neuropathology in diabetic, estrogen-treated ovariec-tomized female rats subjected to transient forebrain ischemia. J Pharmacol Exp Ther. 2006;317:19-29.
26. Brinker G, Pillekamp F, Hossmann KA. Brain hemorrhages after rt-PA treatment of embolic stroke in spontaneously hypertensive rats. Neuroreport. 1999;10:1943-1946.